Skip to content
Screener

Xenon Pharmaceuticals XENE Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue-
EPS-$1.11Beat by $0.03
EPS estimate-$1.14

Next report

Nov 2, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$1.17

Financials

Q2 2026

Income statement

See full
Revenue-—
Operating income-$123.2M-30.7%
Net income-$110.7M-30.7%
EPS (diluted)-$1.11-3.7%

Balance sheet

See full
Cash & equivalents$119.5M-11.7%
Total debt$6.4M-26.4%
Total equity$1.2B+96.0%
Total assets$1.3B+92.2%

Cash flow

See full
Operating cash flow-$95.4M-48.5%
CapEx$275.0K+75.2%
Free cash flow-$95.7M-48.6%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$5.5B+94.2%
Enterprise value$5.38B+99.2%

Returns & leverage

See full
Return on equity-43.6%+8.2pp
Debt / equity0×0.0×
Current ratio21×+5.9×

FAQ

When did Xenon Pharmaceuticals report Q2 2026 earnings?
Xenon Pharmaceuticals (XENE) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Xenon Pharmaceuticals's Q2 2026 revenue and EPS?
Xenon Pharmaceuticals reported revenue of - and eps of $-1.11 for Q2 2026.
Did Xenon Pharmaceuticals beat estimates in Q2 2026?
EPS beat the consensus estimate of $-1.14 by $0.03.
How did Xenon Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 3.7% from $-1.07.
Where can I find Xenon Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-338019) and the 10-Q periodic report (0001193125-26-338244) directly on SEC EDGAR. The filing index links above go to sec.gov.